We studied 15 children ofpreschool age who had obst ructive sleep apnea syndrom e to evaluate thei r dentof acial morph ology in relation to the pharyngeal airway spac e. We fo und that (1) sleep apnea was often associated with mandibular retrognathia , (2 ) the lower incisors tended to exhibit a retroclin e, (3) there were no signific ant differences in angular and linear measurements in the cranial base between pat ients with sleep apnea and a control group of30 nonapn eic children, and (4) the apn eic children had a narrower epipharynge al airwa y space than did the controls. These findin gs suggest that obstructive sleep apn ea is probably caused by both adenoidal hypertrophy and abnormal developm ent ofthe f acial skeleton. We highly recomm end cephalometric analysis as a valuable tool fo r conducting the presurgical evaluation of sleep apnea in children ofpreschool age.
Introduction
Ob stru ctive sleep apnea syndro me (OSAS) is characterized by the recurrent interruption of breathing during sleep .' Beginning at middl e age , OS AS ca n cause episodes of "near miss" death from circulatory disturb anc es/ in add ition to traffi c and othe r acci dents as a result of hypersomnolence.' In children, OSAS can induce growth disord ers. ' Th e primary cause of obstructiv e airway diseases in adu lts is obes ity. In children who are in the primary dentiti on stage , the major cause of OSAS is hypertrophy of the aden oids and tonsils. Alth ough OS AS in adults has long been the subject of study, in children it has only recentl y attracted attenti on." !"
In th is article, we descr ibe ou r evaluation of the de ntofacial morph ology in relation to the pharyn geal air way space in OSAS patient s of presch ool age with prim ary dent ition.
Subjects and methods
Pati ents and control groups. Our patient population was made up of 15 dentate Japanese presch ool childre n-I I boys and 4 girls, aged 3 to 5 years (mea n: 4.7)-who had docum ented OSAS . We used a standardized grading classificati on devised by Kawashim a that is based on the relationship of the tonsils to the oro pharynx in the medi al to lateral plan e as measured betw een the anterior pill ars." Their bod y mass inde x ranged from 14 to 19 (mean: 16.5 ).
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the NA-CF plane and the CF-A plane . An apneic episode was defined as the cessation of airflo w at the nose and mouth for more than 10 seconds. J The apn ea index-that is, the mean numb er of apneic episodes per hou r of sleepwas calculated for each patient , and it ranged from 5 to 18 (mea n: 12.5).
None of the 15 patient s was obese, and none had anatom ic craniofac ial abnormalities, neurologic disease, or cor pulm onale. The control gro up co nsisted of30 children who did not snore, who had no history of respiratory disorders, and who did not experience daytime somnolence. Evidence for the absence of snoring and apneic episodes was obtained from their parents. All the children in the co ntro l group had norm al occlu sion .
Cephalometric analysis. We obtained lateral ce phalometric radiographs while each subject was standing in a natural positi on with his/her head inside the cephalometer . All ceph alogram s were obtained before any medic al or surgical intervention was undert aken .
We used the de finiti ons of landmarks, planes, and measurem ent s proposed by Ricketts (figures 1-3).1J We measured airway dim ensions according to the cephalometric airway analysis methods descr ibed by MeNam ara' ! a nd Sc hulho f'" S L-I to mandib ular plane: The ang le betwee n the L-t plane and the mandibul ar plane.
-PTVplane
Crani al defl ect ion: The ang le between the FH plane and the BA-NA plane.
2 NA-S-B A: The angle between the NA-S plan e and the S-BA plane.
1 Inci sor o verje t: The horizont al distance between the upper incisor edge and the lower incisor edge.
2 Incisor overb ite: The vertical distance between the upper incisor edge and the lower incisor edge.
3 Interin cisal ang le: The angle between the U-l plane and the L-l plane. 
Cephalometric landmarks and reference lines used in this study

D-AD2
The dis tance between the PNS poi nt and the nearest ade no id tis sue, measured along a line from the PNS poi nt perpendic ular to the S-B A plane.
D-P T V
The distance between the nearest ade noid tissue and a point on the PTY plane 5 mm above the PNS po int.
-PTVplane
Upper pharynx T he shor tes t distan ce fro m the upp er surface of the palatine ve lum to the ade no id tissue.
Lower ph aryn x
The distance between the intersection point where the tongu e base meet s the lower conto ur of the mandib le and the posterior pharyn geal wa ll. XI A point located at the center of the ramus (figure 1). The location of XI is keyed geometrically to the FH and PTV planes in four steps: (1) Planes are constructed perpendicular to the FH and PTV planes. (2) These constructed planes are tangent to points (R1, R2, R3, and R4) on the borders of the ramus. (3) The constructed planes form a rectangle enclosing the ramus. (4) XI is located in the center of the rectangle at the intersection of diagonals .
Li nes Facial ax is plane A line connecting the PT and GN points (figures 1, 3).
Facial plane A line connecting the NA and Pog points (figures 1, 3). Ramus plane A tangent line on the posterior contour of the ramus ascendens (figure 1).
U-1 The maxillaryincisorline (figure2).
Continued fro m page 500 (table 1) . We also found significant differences in the values of the interincisal angle (p<O.OO 1) and the L-I to mandibular angle (p<O.OO 1) (table 2) . At the cran ial base, there were no significa nt differences with regard to any angular and linear measurements (table 3) .
Pharyngeal airway structure. There were significa nt differences between the two groups in the size of the upper (p<O.OO I) and lower (p<O .05) pharyn x (table 4) .
Discussion
The three types of sleep apnea are central, obstructive, and mixed. In OSAS, an obstruct ion of the upper respir atory tract prevents air from entering the lungs despite vigorou s thoracic movement. Among the causes of the obstructio n are redund ant tissue in the upper airway , an increase in co mpliance of the pharyngeal wall, and a 502 dorsally positioned tongue in the presence of a short posterior pharyngeal wall. Our study was designed to evaluate dentofacial morp hology in chi ldren with OSAS. Accordingly, our subjects did not have any anatomic, neurologic, or secondary cardiopulmonary m anifestations.
Regarding the mand ible, we noted differences in both form and position. OSAS patients tend ed to have a posteriorly positioned and posteriorly rotated mandible with a higher gonial angle, a longer lower facial height, a greater mandibular plane angle, and a moderately retracted chin. We confirmed that preschool children with OSAS have mandibular retrognathia just as adults with OSAS do. 14 ,15 In patients who are still growing, obstruction of the upper airway can lead to exces sive vertical facial development. Lyberg tunction, care should betaken in dose selection, and maybe useful to monitor renal lunction. (See CLINICA L PHARMACOLOGY). AOVERSE REACTION S Seasonal AllergicRhinitis . Adult s. In placebo-controlled seasonal allergic rhinitis clinical trials in pati ent s 12 years 01 age and older , which included 2461 pati ents receiving fexolenadinehydrochloride capsulesat doses 0120 mgto 240mgtWICe dall y, adverse events were simil arin fexofenadine hydrochlorideandplacebo-treated patients. All adve rse eve nts t~a t were reported by greater than 1% of patients who received the reco mmended daily dose 01 texote nadlne hydrochloride(60mgcapsules twicedaily), and thatweremore common with texoienadlnehydrochlOridethan placebo, arelistedin Table 1 . In a placebo-controll edclinicalstudy in theUni tedStates, which included 570patient s aged 12years andolder recei vinglexclenadinehydrochloride tablets at doses01120or 180 mg once dally, adverse event s were Similar in lexclenadine hydrochloride andplacebo-treated pati ent s. Table 1 alsolists adverseexperiences thatwerereport edby greater than2% of patients treated with lexofenadine hydrochloride tablets at doses 011 80 mg oncedaityand thatweremorecommonvllth texotenadinẽ~~r~~~i~~~C e e t~n : d~;~eo · e ven t s . including drowsiness. was not dose-related and was similar across subgroups defined by age, gender, andrace. 2.8% 1.4% The frequency and magnitude of laboratory abnormalities were similar in lexofenadinehydrochloride andplacebo-treat edpatient s, Pediatr ic. Table 2 lists adverse experi ences in patients aged 6 to 11yea rs 01age which were reported by greater than 2% of patients treated with fexolenadi ne hydrochlori de tabletsat a dose ot 30 mg twice dail y in placebo-controlledseasonal allergic rhinitis studies in the United States andCanada that were morecommon withlexofenadine hydrochloridethan placebo. . . Adverse events reportedby pati ent s 12years 01 ageand olderIn placebo-contr olledchrome idlopathlc urticaria studies were similar to those reported in placebo-controlled seasonal allergic rhinitis studies. In placebocontrolled chronic idiopathic urticar ia clinical trials. which included 726 . pati ent s 12 years of age andolder receiving fexofenadinehydrochloridetabl ets at doses 0120to 240 mg twice dally, adverseevent s wereSimilar in lexotenadine hydrochloride and placebo-treated pati ent s, Table. 3 lists adver seexpenencesIn pat ients aged 12years and olderwhich werereportedby greaterthan2"10 01 patient s treat edWith texotenadmehydrochlonde 60 mg tabl ets twice dai ly in controlled clinicatstudies in the United States and Canada and that weremore common with lexolenadine hydrochloride thanplacebo. Thesalety of fexofenadine hydrochloride in the treatment 01 chronic idiopathic urticaria in pediatric patients 6 to 11 years ot age is based on thesatety protile 01 fexolenadi nehydrochloridein adults and adolescent patients at doses equal to or higher thantherecommended dose (seePediatric Use).
Drug c~1l :c~i , J~: :~~r y C. There was no evidence 01teratogenicity in rats or rabbits at oral doses of U I (which ledto lexol enadi ne exposures that were approxi mately 4 and31 times, resp e<: t i v e~, theexposureIrom Ihemaximumrecommended dail y oraldose ollexolenadin e in adults). Ther eare noadequate andwell controll ed studies in pregnant women. Fexolenadine should be used during pre gnancy onlyit the potential benetit justilies the potential risk to thefetus. Nonlernlogenic Effects. Oose-relateddecreasesin pup weight gai n and survival were observed in rats exposed toan or~dose 01 150 mg/l<gottertenadi ne (approximately 3 times themax imum recommended daily oraldose 01 I"olenadinehydrochlorideinadul ts based oncomparison 01 fexolenadine hydrochlorideAUCs), l l i ! Jl i ng M ol heT hereare noadequateandwel1-eontrolled studies in women duringlact ation. Because many drugs are excreted in humanmilk,caution should be exercised when fexofenadine hydrochloride is administered to a nursing woman.
. . .
Therecommended dose In patents6 to 11years 01 age ISbased on cross-studycomparison 01the pharrnacokinel ics 01 ALLEGRA inadulls and pediatric pati ents and onthe safetyprofile of lexofe nadinehydrochloride in bothadultandpediatricpatientsat doses equal to or higherthanthe recommendeddoses. . Thesalely 01ALLEGRA~bl e t s at a dose 01 30 mg twicedaily has been demonst ratedin 438 pediatric patient s 6to11 yea~01 ag"n~' I O plac ebo-controlled 2-week seasonal all ergi c rhinitis trials. The sal etyof ALLEGRAlor thetreatmentof chronicidi opathic urticar ia in patients 6 to 11 years of ageis basedoncross-studycomparison 01the phannacokinehcs 01ALLEGRAin adultandpedi atric pat ientsand onthe satety profile 01 texotenadinein both adu! and ped" tncpatentsatdoses equalto or higherIhanthe recommended dose. Tl1e ellediveness 01 ALLEGRA lor thetreatment 01seasonal allergic rhinitis in patients 6 to 11years 01 agewas demonslml ed in one tnal (n~4t l ) in which ALLEGRA tablets 30 mg twice daily signilicantly reduced total symptomscores compared to placebo, along with ext rapolation 01 demonstrated etlicacy in patients ages 12yearsand above,andthepharmacokinetic comparisons in adults and children. Theeffectiveness of ALLEGRA lorthetreal mentotchronicidiopalhic urticariain patients 6 to 11 years 01 age is basedon an extrapolation of the demonst raled efficacy 01 ALLEGRA in adults with this conditi onand the likel ihoodthat thedisease course, pathophysiol ogyand the drug's elfect aresubstantially similar in chi ldren to that of adult patients. The sal e~andelfecliveness01ALLEGRA in pediatric patients under 6 years 01 age havenot been established, G!Iialri c.!Jg C linical st udies otALLEGRA tablets and capsules did notincl udesufficient numbers 01SUbjects aged 65years arid o'~r to determine whether this population responds differenll y Irom younger pat ients. Other reported clinical experience hasno t identifieddifferences in responses betweenthe geriatric andyounge r patients. Thi s drug istn"mtobesubstantiallyexcreted by the kidney, and the risk 01toxic reactions to this drug may be greaterinpatienlswithimpairedrenal function. Because elderly patients aremorelikely to havedecreased renal Eryt hromycin (500 mgevery 8hrs) Kel oconazole t 135% +164% (400mg oncedailyj Thechanges inplasma levels werewithin the range 01plasma level s achievedinadequat eand well-controlled clinical trials.
Themechanismof Iheseinteractions has beenevaluated in in vitro, in si tu, and in viv o animal models. These studies indicate that kel OConazoleorerythromycinco-admi nistration enhances fexofenadinegastroi. O .l eslinal.absorP.tion. In vi v~animal studies alsosuggest that in addition 1 0 increasing absorption, ketoconazole decr eases lexolenadine hydrochloride gastrointestinal secretion, while erythromycin mayalsodecrease biliaryexcretion. l!n!!l lnternclionswilhAnlaci ds Admin.tmtion 01120mgot lexolenadine hydrochloride (2 x 60 mg capsule) within. 15 minutes of an aluminum and magnesium conlaining antaCid (Maalox'j decreased lexofenadine AUC by 41% and C m " by 43%. ALLEGRA shouldnot betaken closel y in timewith aluminumandmagnesIUm contam mg antacids. CM-cinog enesis MU l a g~nesl s Impairment or Fertility Thecarcinogenicpntent laland reproductivetoxicity 01texolenadine hydrochloride wereassess ed using terfenadine studies with adequatelexolenadin e hydrochloride exposure (based on plasma area-under-t he-concentr ation vs .lime IAUG ) values). Noevidence 01 carc inogenici ty wasobserved in an 18-month studyin mice and in a24-monthsludy In ratsatoral dosesup to 150mglkg 01terfenadine (which led to lexofenadineexposuresthat lVererespectiv elyapprox imately 3 and 5 times the exposurefrom the maximum recommended daily oraldose 01 fexolenadinehydrochlor ide inadults andchildren), In in vitro (Bacterial Reverse Mutation, CHOIHGPRT Forward Mutation, and Ra t Lymphocyt e Chromosomat Abermtion assays) and in viv o (Mouse Bone Marrow Micronucleusassay) tests, Iexotenadlne hydrochloride revealed noevidence otmutagenicity.
In rat fertilitystudIes. dose-relat ed reductions in implant s and increases in postimplantati on losses were obselVed alan oral dos e01150mglkg 01terlenadine (which led to lexotenadine hydrochloride exposures that lVere a pp r ox i m a t e~3 times the exposure 01 the maximum recommended dail y oral dose ot fexolenadine hydrochlor ideinadulls). Fexolenadmehydrochl ollde has been shown to exhibit minimal (ca. 5%1 metabolism. However, co-admi nistration of fexofe nadi ne hydrochloride" nth ketoconazole anderythromyci n ledto increased plasma levels 01 lexolenadine hydrochloride. Fexolenadine hydrochloride hadnoeilect onIhe pharmacokinetics of erythromycin and ketoconazole. Intwoseparate studies, lexofenadine hydrochloride 120 mg~1J<e dally (two hmes the recommended twice dally dose)"osco ·administeredwit herythromycin 500mgevery8 hours or keloconazole400 mg once dailyunder steady-stateconditions to normal, healthy volunteers ( n~24 , each studv). No difference s in adverse event s or aT c . interval were observed when patients were administered f exo l e na~me hydrochloride alone or in combination wit herythromyc inorketoconazole.Thefindings of these studies are summar ized inthelollowing inclination and the height ofthe anterior face were slightly greater in adu lts with OSAS-findings that are similar to ours in children. P:" However, none of the children with OS AS in our study had mandibular micrognathia. We believe that presc hoo l ch ildren with OSAS should be treated for ske leta l problems by a pediatric denti st. T he lower incisors in the children with OSAS tended to exhibit a retroc line. Linder-Aron son repo rted that children with adenoid hype rtrop hy tend to have retrocl ined . upp er and lower incisors and a sma ll overb ite. I ?
In adults with OSAS, the entire structure of the cranial base has been reported to be rota ted slightly cou nterclockwise in the sag ittal plane, " but we did not observe a similar counterclockwise rotation in children.
In our study, the chi ldren with OSAS had a narrower epipharyngea l airway space than did the con tro ls and a significantly larger value with regard to the height of the lower pharynx . Therefore, in the OSAS childre n, the root of the tongue was noted to be in an anterior position . The mandibular position clearly had an impact on the size of the posterior airway space.
Altogether, this study indicates that the retromandibular space, as meas ured by lateral cep ha lography, is sma ller in most ch ildren with OSAS and appears to prov ide insufficie nt space for the tongue in the pharyngeal cavi ty. The pri mary ca use of obstructive airway disease in children is hype rtrophy of the adenoi d and faucia l tonsil s, and we recommend a surgical approach for management."
Although polysomnography is routinely performed to eva luate children with OSAS , normal poly somnographic values for children in the preschoo l-age group have not yet been estab lished . Marcu s et al found that polysom-Tab le 2. Comparison of denture patt ern in the OSAS and con trol groups Incisor overjet (rnrn) Incisor overbite (mm) Interinc isal angle (0) U-1 to FH plane (0) L-1 to mandibular plane (0) *Not statistically signi fica nt. nograph ic res ult s in children differ from those in ad ults, and that the cl inical sign ificance of short apneic epi sodes in children has not yet bee n ascertained. IX Th erefore, we recommend a combination of morphologic and functional dia gnosis .'?
